Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Increases By 33.0%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 23,800 shares, a growth of 33.0% from the September 15th total of 17,900 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average trading volume of 95,500 shares, the short-interest ratio is currently 0.2 days.

ZyVersa Therapeutics Stock Down 1.7 %

Shares of NASDAQ:ZVSA opened at $2.28 on Tuesday. The business’s 50 day moving average price is $2.62 and its 200-day moving average price is $4.15. ZyVersa Therapeutics has a 1 year low of $2.08 and a 1 year high of $47.25.

ZyVersa Therapeutics (NASDAQ:ZVSA) last issued its quarterly earnings results on Friday, August 9th. The company reported ($3.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.20) by $1.89. As a group, equities research analysts anticipate that ZyVersa Therapeutics will post -22.7 EPS for the current year.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.